标题:NHL患者血清 IL-21的表达及临床意义
作者:陈迪,杨敏,任明强,陈琦 (遵义医学院附属医院血液内科,贵州 遵义 563000)
卷次:
2018年29卷8期
【摘要】 目的 检测非霍奇金淋巴瘤(NHL)患者血清中白细胞介素21 (IL-21)的表达水平,探索 IL-21与NHL的发病及预后的相关性。方法 选择2015年12月至2016年12月遵义医学院附属医院收治的NHL患者36例(初诊患者20例,化疗后患者16例),以同期13例健康志愿者为对照组,应用酶联免疫吸附试验(ELISA)检测NHL患者治疗前后和对照组人群的血清 IL-21水平,比较初诊NHL患者血清 IL-21水平在年龄、性别、分期、分组、有无结外浸润等临床因素有无差异,分析治疗前后NHL患者血清 IL-21水平的变化。结果 NHL患者血清 IL-21水平为(200.75±58.91) ng/L,明显低于对照组的(420.91±132.56) ng/L,差异具有统计学意义(P<0.05);初诊NHL处于Ⅲ期和Ⅳ期患者血清 IL-21水平为(153.77±25.97) ng/L,明显低于Ⅰ期和Ⅱ期患者的(223.87±35.36) ng/L,差异具有统计学意义(P<0.05);有全身症状者血清 IL-21水平为(141.15±17.95) ng/L,明显低于无全身症状者的(208.46±33.50) ng/L,差异具有统计学意义(P<0.05);有结外浸润者血清 IL-21水平为(143.94±19.38) ng/L,明显低于无结外浸润者的(212.53±32.80) ng/L,差异具有统计学意义(P<0.05);治疗前患者血清 IL-21水平为(162.63±38.75) ng/L,明显低于治疗缓解后患者的(264.45±43.89) ng/L,差异具有统计学意义(P<0.05)。结论 IL-21表达水平与NHL的分期、分组、有无结外浸润有关,IL-21的表达水平可能与NHL的发病及预后有关。
【关键词】 非霍奇金淋巴瘤;白细胞介素21;表达;酶联免疫吸附试验
【中图分类号】 R733.4 【文献标识码】 A 【文章编号】 1003—6350(2018)08—1111—03
Expression and clinical significance of serum IL-21 in patients with non-Hodgkin's lymphoma.
CHEN Di, YANGMin, REN Ming-qiang, CHEN Qi. Department of Hematology, the Affiliated Hospital of Zunyi Medical University, Zunyi563000, Guizhou, CHINA
【Abstract】 Objective To investigate the expression and clinical significance of serum interleukin-21 (IL-21)in patients with non-Hodgkin's lymphoma (NHL). Methods A total of 36 patients with NHL admitted to Department ofHematology of the Affiliated Hospital of Zunyi Medical University from December 2015 to December 2016 were select-ed as the research subjects, including 20 initially diagnosed patients and 16 patients after chemotherapy. Meantime, 13healthy volunteers were enrolled as the control group. The levels of IL-21 in serum were determined by enzyme-linkedimmunosorbent assay (ELISA) to investigate its relationship with age, sex, stage, grouping, with or without internal andexternal organ infiltration and other clinical factors. The serum IL-21 levels changes in patients with NHL before and af-ter chemotherapy were analyzed. Results The levels of IL-21 in NHL patients was lower than those in controls,(200.75±58.91) ng/L vs (420.91±132.56) ng/L, P<0.05. Compared with newly diagnosed NHL patients of stage Ⅰ andⅡ, the levels of IL-21 decreased markedly in patients of stageⅢ andⅣ, (153.77±25.97) ng/L vs (223.87±35.36) ng/L,P<0.05. The levels of IL-21 in patients with systemic symptoms were significantly lower than those without systemicsymptoms, (141.15±17.95) ng/L vs (208.46±33.50) ng/L, P<0.05. Moreover, compared with infarcted organ infiltrationgroup, the content of IL-21 declined significantly in extranodal organ infiltration group: (143.94±19.38) ng/L vs (212.53±32.80) ng/L, P<0.05. The serum IL-21 level in patients with NHL after treatment remission was significantly higher thanthat of NHL before treatment: (264.45±43.89) ng/L vs (162.63±38.75) ng/L, P<0.05. Conclusion The expression levelof serum IL-21 is related to the staging, grouping and extranodal invasion of NHL. The level of serum IL-21 may be as-sociated with the pathogenesis and prognosis of NHL.
【Key words】 Non-Hodgkin'slymphoma; Interleukin-21; Expression; Enzyme-linked immunosorbent assay·论 著·doi:10.3969/j.issn.1003-6350.2018.08.022
下载PDF